Current Situation and Prospect of Pharmacoeconomic Evaluation of Hemophilia in China
10.12376/j.issn.2097-0501.2022.04.018
- VernacularTitle:中国血友病药物经济学评价研究的现状与展望
- Author:
Shunping LI
1
;
Lei DOU
1
;
Yunhai FANG
2
Author Information
1. Centre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.NHC Key Lab of Health Economics and Policy Research (Shandong University), Jinan 250012, China.Center for Health Preference Research, Jinan 250012, China.
2. Bolld Center of Shangdong Province, Shandong Province Hemophilia Treatment Center, Jinan 250014, China.
- Publication Type:Journal Article
- Keywords:
hemophilia;
pharmacoeconomics;
evaluation
- From:
JOURNAL OF RARE DISEASES
2022;1(4):468-473
- CountryChina
- Language:Chinese
-
Abstract:
In 2018, hemophilia, one of the first ones, entered into the catalogue of Rare Disease in China. However, drug accessibility and affordability have been the challenges for hemophilia patients. Therefore, a comprehensive evaluation of the cost and efficacy of hemophilia drugs is essential to push forward the appropriate application of hemophilia drugs. In the article, we have teased out the existing process of the review and approval of hemophilia drugs; have examined the procedures for the drug entry into the medical insurance policy; have systematically searched the pharmacoeconomic evaluation studies of hemophilia in published literature in both China and overseas; and have comprehensively analyzed the quality, the content of evaluation, and challenges of pharmacoeconomic studies of hemophilia in China. At last, we discuss the prospect for the future based on the following three aspects: developing a special model of hemophilia, obtaining the health utility from various sources, and establishing the threshold of willingness to pay for rare diseases, hoping to provide reference and examples to the research into pharmacoeconomic evaluation of hemophilia in China.
